Octreotide acetate, a synthetic analog of the natural hormone somatostatin, is a potent inhibitor of growth hormone, glucagon, and insulin. Initially synthesized in 1979, Octreotide is primarily researched to treat acromegaly, a condition caused by excess growth hormone, and symptoms associated with neuroendocrine tumors, such as carcinoid syndrome and vasoactive intestinal peptide-secreting tumors (VIPomas).
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | Octreotide, Sandostatin, SMS 201-995 |
|---|---|
| IUPAC Name | (4R, 7S, 10S, 13R, 16S, 19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R, 3R)-1, 3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6, 9, 12, 15, 18-pentaoxo-1, 2-dithia-5, 8, 11, 14, 17-pentazacycloicosane-4-carboxamide |
| CAS | 79517-01-4 |
| Molecular Weight | 1019.2 |
| Molecular Formula | C49H66N10O10S2 |
| SMILES | C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O |